SCHEMBL9963097

SCHEMBL9963097

CC(C)n1nnc(CN2CCNCC2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.38
▸ SIGMAR1 Q99720 2/20 0.35
▸ CXCR4 P61073 7/20 0.35
▸ LMNA P02545 1/20 0.34
▸ CHRM2 P08172 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ ADRA2C P18825 1/20 0.33
▸ CCR2 P41597 1/20 0.33
▸ CXCL12 P48061 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ CHRM5 P08912 1/20 0.32
▸ CHRM3 P20309 1/20 0.32
▸ TMEM97 Q5BJF2 1/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1514756 0.87 HRH4 (0.36) PTPN1SIGMAR1HRH3CHRM5CHRM3
SCHEMBL9934258 0.78 PTPN1 (0.40) PTPN1SIGMAR1CXCR4LMNACHRM2
SCHEMBL9963099 0.68 ALDH1A1 (0.68) SIGMAR1LMNAMEN1KMT2AALDH1A1
SCHEMBL1303314 0.65 — —
SCHEMBL19203825 0.65 CXCR4 (0.44) SIGMAR1CXCR4LMNACHRM2MEN1
SCHEMBL16302786 0.65 ALDH1A1 (0.69) SIGMAR1LMNAMEN1KMT2AALDH1A1
SCHEMBL20322779 0.64 SIGMAR1 (0.38) PTPN1SIGMAR1CXCR4LMNACHRM2
SCHEMBL26580974 0.63 CXCR4 (0.42) PTPN1SIGMAR1CXCR4LMNACHRM2
SCHEMBL9934708 0.63 GABRA1 (0.34) MEN1KMT2A
SCHEMBL15266356 0.62 LMNA (0.39) SIGMAR1CXCR4LMNACHRM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 — — US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 — — US disclosed
WO-2011025690-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2011-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 PTPN1 3783/4885SIGMAR1 152/4885CXCR4 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback